Novartis has provided updated data from phase 3 trials of ZOLGENSMA (onasemnogene abeparvovec-xioi) for patients with spinal muscular atrophy. …
Latest Video
New Stories
-
Pricing proposal will 'destroy' the industry and halve drug approvals
October 17, 2019 - - Latest News -
US proposal a 'game over' moment for Australian access
October 17, 2019 - - Comment -
How the federal government gets to 2,200 'medicines'
October 17, 2019 - - Latest News -
Threshold legislation sparks renewed PBS debate
October 17, 2019 - - Latest News -
Department of Health: Ask the minister's office
October 16, 2019 - - Latest News -
Chris Bowen: Government 'not really telling the truth' on PBS
October 16, 2019 - - Latest News -
PSA confirms appointment of new CEO
October 16, 2019 - - Latest News